DNLI - Denali Therapeutics Inc.
| Previous Close | 22.36 |
| Open | 22.12 |
| Bid | 21.73 x 900 |
| Ask | 21.81 x 800 |
| Day's Range | 21.09 - 22.32 |
| 52 Week Range | 14.24 - 28.86 |
| Volume | 245,501 |
| Avg. Volume | 395,506 |
| Market Cap | 2.093B |
| Beta (5Y Monthly) | 2.11 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.69 |
| Earnings Date | Nov 05, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 25.90 |
- Zacks
Novavax Rises on Fast Track Designation to Influenza Vaccine
The FDA bestows a Fast Track Designation on Novavax's (NVAX) influenza vaccine candidate NanoFlu for adults aged 65 years and older. Shares rally.
- Zacks
Perrigo (PRGO) Rises on Stellar Q419 Preliminary Results
Perrigo (PRGO) announces better-than-expected preliminary results for fourth-quarter 2019 as well as the full year. Shares gain.
- Zacks
Denali Therapeutics Sees Hammer Chart Pattern: Time to Buy?
Denali Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.
- Zacks
Emergent (EBS) Posts Preliminary '19 Results, Gives 2020 View
Emergent (EBS) narrows revenue view for 2019 and expects a consistent rise in Narcan nasal spray sales during 2020.
- GlobeNewswire
Denali Therapeutics Announces Broad Pipeline Progress Including Positive Results From Its LRRK2 Program for Parkinson’s Disease
LRRK2 inhibitor DNL201 Phase 1b demonstrated high levels of target and pathway engagement and improvement of lysosomal biomarkers in patients with Parkinson’s disease LRRK2.
- Simply Wall St.
Denali Therapeutics (NASDAQ:DNLI) Is In A Strong Position To Grow Its Business
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
- PR Newswire
Flagship Unveils Newest Pioneering Platform: Ring Therapeutics
Flagship Pioneering, a unique life sciences innovation enterprise, today announced the launch of Ring Therapeutics, an early-stage biotechnology company developing first-in-class gene therapies using a new viral vector platform based on its groundbreaking work on the human commensal virome. Ring's technology promises to address many of the limitations of current DNA and gene therapies, such as limited access to diverse tissues, inability to redose, risk of genomic integration, and poor tolerability. Ring's founding and continued development are resourced by an initial capital commitment of $50 million from Flagship Pioneering.
- Insider Monkey
Denali Therapeutics Inc. (DNLI): Are Hedge Funds Right About This Stock?
At Insider Monkey, we pore over the filings of nearly 750 top investment firms every quarter, a process we have now completed for the latest reporting period. The data we've gathered as a result gives us access to a wealth of collective knowledge based on these firms' portfolio holdings as of September 30. In this […]
- Zacks
Options Traders Expect Huge Moves in Denali (DNLI) Stock
Investors need to pay close attention to Denali (DNLI) stock based on the movements in the options market lately.
- Zacks
Denali Therapeutics Inc. (DNLI) Reports Q3 Loss, Tops Revenue Estimates
Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of 9.43% and 25.24%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Denali Therapeutics Reports Third Quarter 2019 Financial Results and Business Highlights
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2019 -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for.
- Insider Monkey
Were Hedge Funds Right About Ditching Denali Therapeutics Inc. (DNLI)?
The first quarter was a breeze as Powell pivoted, and China seemed eager to reach a deal with Trump. Both the S&P 500 and Russell 2000 delivered very strong gains as a result, with the Russell 2000, which is composed of smaller companies, outperforming the large-cap stocks slightly during the first quarter. Unfortunately sentiment shifted […]
- GlobeNewswire
Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL151 for Parkinson’s Disease and Launch of Its Engage Parkinson’s Website
Denali Therapeutics Inc. (DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today announced initiation of dosing in a Phase 1b clinical study of LRRK2 inhibitor DNL151 in patients with Parkinson’s disease, and the launch of its Engage Parkinson’s website. “Based on data generated from our prior study in healthy volunteer subjects, we are excited to evaluate DNL151 in Parkinson’s disease patients,” said Carole Ho, M.D., CMO.
- Zacks
Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Lags Revenue Estimates
Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -32.61% and -7.06%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Denali Therapeutics Reports Second Quarter 2019 Financial Results and Business Highlights
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2019 -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for.
- GlobeNewswire
Denali Therapeutics Announces That Its Partner Sanofi has Commenced Dosing of DNL758 in a Phase 1 Study
Sanofi has commenced dosing of DNL758 in a Phase 1 healthy volunteer study. Denali will receive a $10 million clinical milestone payment from Sanofi. SOUTH SAN FRANCISCO, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today announced that its partner Sanofi has commenced dosing of DNL758, a peripherally restricted small molecule inhibitor of RIPK1, in a Phase 1 healthy volunteer study.
- Zacks
Denali Therapeutics Inc. (DNLI) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Denali Therapeutics Inc. (DNLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
Is Denali Therapeutics Inc. (NASDAQ:DNLI) A Financially Strong Company?
Small and large cap stocks are widely popular for a variety of reasons, however, mid-cap companies such as Denali...
- Insider Monkey
Hedge Funds Have Never Been This Bullish On Denali Therapeutics Inc. (DNLI)
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than 700 world-class investment firms that we track and now have access to the collective wisdom contained in […]
- Zacks
Denali's Hunter Syndrome Candidate Gets Orphan Drug Status
The FDA assigns an orphan drug designation and a rare pediatric disease designation to Denali's (DNLI) pipeline candidate, DNL310, for treating patients with Hunter Syndrome. Shares inch up.
- GlobeNewswire
Denali Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designation for DNL310, and Expands its Portfolio of Brain Penetrant Enzyme Replacement Programs
Denali Therapeutics Inc. (DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today announced that the FDA granted Orphan Drug Designation (“ODD”) and Rare Pediatric Disease Designation for Denali’s DNL310 program, which Denali is developing for patients with mucopolysaccharidosis II (“MPS II” or Hunter Syndrome). DNL310, or ETV:IDS, is a recombinant form of the iduronate 2-sulfatase (“IDS”) enzyme engineered to cross the blood-brain barrier (“BBB”) using Denali’s proprietary ETV technology.
- Zacks
Denali Therapeutics Inc. (DNLI) Reports Q1 Loss, Lags Revenue Estimates
Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -10.81% and -67.35%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Denali Therapeutics Reports First Quarter 2019 Financial Results
SOUTH SAN FRANCISCO, Calif., May 08, 2019 -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for.
- Zacks
Analysts Estimate Denali Therapeutics Inc. (DNLI) to Report a Decline in Earnings: What to Look Out for
Denali Therapeutics Inc. (DNLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
